Short Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Increases By 202.9%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 2,070,000 shares, an increase of 202.9% from the November 15th total of 683,300 shares. Based on an average trading volume of 15,090,000 shares, the days-to-cover ratio is currently 0.1 days.

CNS Pharmaceuticals Stock Performance

Shares of NASDAQ:CNSP traded down $0.00 during midday trading on Wednesday, hitting $0.11. 2,298,439 shares of the stock were exchanged, compared to its average volume of 5,588,560. The business’s 50-day moving average price is $0.12 and its 200 day moving average price is $1.18. The stock has a market capitalization of $6.16 million, a price-to-earnings ratio of 0.00 and a beta of 2.55. CNS Pharmaceuticals has a 12 month low of $0.10 and a 12 month high of $100.50.

Analysts Set New Price Targets

Separately, Maxim Group upgraded CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Tuesday, September 10th.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.